Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 127 (2007).
Multiple sclerosis: management of multiple sclerosis in primary and secondary care. NICE clinical guideline 8 (2003).
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. NICE technology appraisal guidance 32 (2002).